Koers Compugen Ltd. TEL AVIV STOCK EXCHANGE
Aandelen
IL0010852080
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 37,9 mln. 14,09 mld. 35,19 mln. | Omzet 2025 * | 35,29 mln. 13,12 mld. 32,76 mln. | Marktkapitalisatie | 180 mln. 66,91 mld. 167 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -13 mln. -4,83 mld. -12,07 mln. | Nettowinst (verlies) 2025 * | -29 mln. -10,78 mld. -26,92 mln. | EV/omzet 2024 * | 4,75 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 5,1 x |
K/w-verhouding 2024 * |
-15,5
x | K/w-verhouding 2025 * |
-7,44
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 94,62% |
Recentste transcriptie over Compugen Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01-01-02 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 01-11-22 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 65 | 02-10-17 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 11-06-18 |
Gilead Halevy
BRD | Director/Board Member | 57 | 11-06-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |